Jang H, Hill NL, Turner J, Bratlee-Whitaker E, Jeong M, Mogle J. Poor-quality daily social encounters, daily stress, and subjective cognitive decline among older adults. Innov Aging. 2024 May 8. doi: 10.1093/geroni/igae038
Turner JR, Hill NL, Brautigam L, Bhargava S, Mogle J. How does exposure to dementia relate to subjective cognition? A systematic review. Innov Aging. 2023 Jun 19. doi: 10.1093/geroni/igad056
Bhargava S, Hill N, Mogle J. Self-reported memory problems are related to depressive symptoms in older adults with certain personality traits. Poster presented at the 2020 Gerontological Society of America (GSA) Annual Scientific Meeting; November 4, 2020. [abstract] Innov Aging. 2020 Dec 16; 4(Supplement_1,2020):389-90. doi: 10.1093/geroni/igaa057.1254
Mogle J, Hill N, Bhargava S, Bell T, Whitaker E. The factor structure of memory complaints over time. Poster presented at the Gerontological Society of America; November 2019. Austin, TX. [abstract] Innov Aging. 2019 Nov; 3(Supp 1):S221.
Hill NL, Mogle J, Bhargava S, Bell TR, Wion RK. The influence of personality on memory self-report among black and white older adults. Presented at the 2019 Gerontological Society of America (GSA) Annual Scientific Meeting; November 13, 2019. Austin, TX. [abstract] Innov Aging. 2019 Nov; 3(Suppl 1):S220.
Rausch DA, Levin M, Meyers J, Candrilli S, Yan S, Krishnarajah G, Patterson B. Cost of diagnosed herpes zoster complications in patients age ≥50 years: a US claims data analysis. Poster presented at the IAGG 2017 World Congress; July 23, 2017. San Francisco, CA. [abstract] Innov Aging. 2017 Jul; 1(Suppl 1):902. doi: 10.1093/geroni/igx004.3234
Schmitt CL, Allen JA, Kosa KM, Curry LE. Support for a ban on tobacco powerwalls and other point-of-sale displays: findings from focus groups. Health Educ Res. 2015 Feb;30(1):98-106. doi: 10.1093/her/cyu046.
MacDougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089
Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.
Spiegel BMR, Locke G, Kurtz CM, Williams VSL, Nelson LM, Carson RT, Currie MG, Schneier HA, Johnston JM. Clinically meaningful change benchmarks for IBS-C symptoms developed using data from two phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep; 24(s2):35.
Nelson LM, Williams VSL, Carson RT, Baird MJ, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBSC): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):106. doi: 10.1111/j.1365-2982.2012.01997.x
Carson RT, Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):179.
Akashi-Ronquest N, Carrillo P, Dembling B, Stern S. Measuring the biases in self-reported disability status: evidence from aggregate data. Appl Econ Lett. 2011 Feb 23;18(11):1053-60. doi: 10.1080/13504851.2010.524603
Mangel AW, Fehnel SE. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterol Motil. 2008 Oct 1;20(10):1086-93.
Doward LC, McKenna SP, Meads DM, Jovell AJ, Fisk J, Eckert BJ. The international development of patient reported outcome indices for multiple sclerosis. Poster presented at the 2006 Sixteenth Meeting of the European Neurological Society; May 2006. Lausanne, Switzerland. [abstract] J Neurol. 2006; 253(Suppl 2):125.
Rousu M, Kosa K. Allowing options in experimental auctions. Appl Econ Lett. 2005;12(13):817-21. doi: 10.1080/13504850500193059